Dosage Forms and Bioavailability
Learning Objectives
- Classify pharmaceutical dosage forms by route of administration: oral, parenteral, topical, and inhalation.
- Define bioavailability and explain why it is central to comparing drug formulations.
- Identify the formulation, physiological, and metabolic factors that raise or lower bioavailability.
- Explain first-pass metabolism and why it makes oral bioavailability almost always less than 100%.
- Apply bioavailability reasoning to real formulation examples such as enteric coatings and iron supplements.
Quick Answer
A dosage form is the physical vehicle — tablet, injection, cream, inhaler — that delivers a drug into or onto the body, and bioavailability is the fraction of that administered dose that actually reaches systemic circulation unchanged and able to act. The two ideas are linked tightly: choosing a dosage form is really choosing how much of the drug will survive the journey to its target and how fast it will get there. This matters clinically because two products with the identical active ingredient can behave completely differently in the body if their formulation changes absorption — which is exactly why regulators require bioequivalence testing before a generic drug can be approved.
How Dosage Forms Shape What Happens to a Drug
Every dosage form is really an engineering answer to the question: "How do we get this molecule from outside the body to its site of action, intact and in the right amount?"
Oral Dosage Forms
Tablets, capsules, suspensions, syrups, and powders are the most common forms because they're non-invasive and easy for patients to self-administer. But convenience comes at a cost: everything swallowed must survive stomach acid, intestinal enzymes, and — before it even reaches general circulation — a pass through the liver.
Parenteral Dosage Forms
Injectables, implants, and (functionally) transdermal patches deliver drugs without going through the gut. Because an IV injection places the drug directly into the bloodstream, it is used as the reference standard of 100% bioavailability against which other routes are compared.
Topical and Inhalation Dosage Forms
Creams, ointments, gels, and patches act locally on skin or mucous membranes with limited systemic absorption — useful when you want an effect at the site of application and want to minimize whole-body drug exposure. Inhalation (aerosols, dry powder inhalers, nebulizers) delivers drug directly to the lungs, which is both a target organ (for asthma/COPD) and, because the lungs are highly vascular, a fast route into systemic circulation when that's the goal.
Bioavailability: The Fraction That Actually Counts
Bioavailability (F) is defined as the fraction of an administered dose that reaches the systemic circulation unchanged. By definition, an intravenous dose has F = 1 (100%), since none of it is lost before entering the blood. Every other route has to "compete" against absorption barriers, so F is typically less than 1.
Why Bioavailability Is Never Automatic
1. Formulation effects. How a tablet is manufactured changes how fast (and whether) it dissolves. Enteric coatings protect a drug from stomach acid so it releases in the small intestine instead — useful for acid-labile drugs, but it also delays onset. Controlled-release formulations spread absorption over hours, lowering peak concentration but extending duration.
2. Route of administration. Oral drugs are exposed to the "first-pass effect" — before an absorbed drug reaches the general circulation, blood from the gut passes through the liver via the portal vein, where metabolizing enzymes can inactivate a substantial fraction of the dose. This is why some drugs (like nitroglycerin) are given sublingually or transdermally — routes that skip the portal circulation entirely.
3. Absorption rate. Particle size, drug solubility, and gastrointestinal pH all influence how quickly a dissolved drug crosses the gut wall. A poorly soluble drug simply may not dissolve fast enough to be absorbed before it passes out of the absorptive window of the small intestine.
4. Metabolism and excretion. Beyond the first-pass effect, ongoing enzymatic degradation (for example, by cytochrome P450 enzymes) can reduce the amount of active drug that ultimately reaches its target, even after absorption.
Applying This: Two Worked Examples
Iron supplements. Ferrous sulfate has higher bioavailability than ferrous gluconate but causes more GI upset — showing that "higher bioavailability" and "better tolerated" are not the same axis, and clinicians must balance both when choosing a formulation for a specific patient.
Antacids. Immediate-release tablets act fast but can cause rebound acid secretion; extended-release capsules act more slowly but sustain relief; liquid suspensions absorb variably depending on the vehicle. The "best" dosage form depends on what symptom pattern the patient actually has.
Key Terms
| Term | Definition |
|---|---|
| Dosage form | The physical vehicle (tablet, injection, cream, etc.) used to deliver a drug. |
| Bioavailability (F) | The fraction of an administered dose that reaches systemic circulation unchanged. |
| First-pass metabolism | Hepatic (and sometimes gut wall) metabolism of an orally absorbed drug before it reaches systemic circulation. |
| Enteric coating | A tablet coating designed to resist stomach acid and dissolve in the intestine instead. |
| Controlled-release formulation | A dosage form engineered to release drug slowly over an extended period. |
| Dissolution | The process by which a solid drug dissolves into solution, a prerequisite for absorption. |
| Bioequivalence | Statistical demonstration that two formulations produce comparable rate and extent of absorption. |
Common Mistakes
Misconception 1: "IV drugs are always more effective than oral drugs because they have 100% bioavailability." Why it's wrong: Bioavailability measures how much drug reaches circulation, not how effective the drug is once it gets there — efficacy also depends on the drug's mechanism, dose, and target. Correct understanding: 100% bioavailability just means none of the administered dose is lost before entering the blood; it does not automatically mean better clinical outcomes, and IV administration carries its own risks (infection, requires trained staff).
Misconception 2: "Enteric-coated tablets always improve bioavailability." Why it's wrong: Enteric coating primarily protects the drug from stomach acid or protects the stomach from the drug — it doesn't inherently increase the amount absorbed and can delay onset of action. Correct understanding: Enteric coating changes where and when absorption happens, not necessarily how much is absorbed; the clinical benefit depends on the specific drug's stability and site of best absorption.
Misconception 3: "Bioavailability is a fixed property of a drug molecule." Why it's wrong: Students often treat bioavailability like molecular weight — an intrinsic constant. Correct understanding: Bioavailability depends on the formulation and route, not just the molecule; the same active ingredient can show very different bioavailability as a suspension versus a controlled-release tablet versus an IV injection.
Comparison and Connections
| Route | Typical Bioavailability | Key Advantage | Key Limitation |
|---|---|---|---|
| Intravenous | 100% (by definition) | Immediate, complete, precise dosing | Invasive, requires trained administration |
| Oral | Variable, often well below 100% | Convenient, non-invasive | Subject to first-pass metabolism and GI variability |
| Sublingual/Transdermal | Often higher than oral for suited drugs | Bypasses first-pass metabolism | Limited to drugs with suitable physicochemical properties |
| Inhalation | High for local lung effect; variable systemically | Fast onset, direct to target organ | Technique-dependent, device cost |
| Formulation Choice | Effect on Bioavailability | Effect on Duration |
|---|---|---|
| Immediate-release tablet | Rapid, often higher peak | Shorter duration |
| Enteric-coated tablet | Delayed onset | Protects drug/stomach, timing shifted |
| Controlled/extended-release | Lower peak, more even level | Longer duration, less frequent dosing |
Practice Questions
Recall 1: What is the bioavailability of an intravenously administered drug, and why? Answer guidance: 100%, because the entire dose enters systemic circulation directly with no absorption barrier or first-pass loss.
Recall 2: List the four major routes of dosage form administration discussed in this chapter. Answer guidance: Oral, parenteral, topical, and inhalation.
Understanding 1: Explain why oral drugs generally have lower bioavailability than the same drug given intravenously. Answer guidance: Oral drugs must survive gastric acid, dissolve, be absorbed across the gut wall, and pass through the liver (first-pass metabolism) before reaching systemic circulation — each step can reduce the amount of intact drug.
Understanding 2: Why might a controlled-release formulation be preferred over an immediate-release one, even though its bioavailability may look "lower" in peak terms? Answer guidance: Controlled release provides a steadier drug concentration over time, reducing peak-related side effects and the need for frequent dosing, which improves patient compliance and reduces trough-related loss of effect.
Application 1: A patient with acid-sensitive medication complains that their tablet seems to "take a while to work." What formulation feature might explain this, and is it a defect? Answer guidance: Likely an enteric coating delaying release until the tablet reaches the intestine; not a defect — it's intentional, protecting the drug from stomach acid, though the trade-off is delayed onset.
Application 2: Two iron supplements are available: one with higher bioavailability but more GI side effects, one gentler but less well absorbed. How would you counsel a patient choosing between them? Answer guidance: Discuss the trade-off explicitly — higher absorption vs. tolerability — and consider patient-specific factors (severity of anemia, history of GI intolerance) to individualize the recommendation.
Analysis 1: Compare how first-pass metabolism and poor aqueous solubility both reduce oral bioavailability, but through different mechanisms. Answer guidance: First-pass metabolism reduces bioavailability after absorption, via hepatic (or gut wall) enzymatic breakdown; poor solubility reduces bioavailability before absorption, because the drug cannot dissolve fast enough to be absorbed across the gut wall. Both lower F, but interventions differ (route change vs. particle size/solubility enhancement).
Analysis 2: A generic manufacturer changes only the inactive excipients in a tablet, not the active ingredient. Explain how this alone could alter bioavailability, and why regulators require bioequivalence testing. Answer guidance: Excipients affect dissolution rate, disintegration time, and sometimes drug stability, all of which can shift how quickly and completely the active ingredient is absorbed — hence identical active ingredients don't guarantee identical clinical performance, which is exactly why bioequivalence (not just chemical identity) is regulated.
FAQ
Does a higher bioavailability always mean a "better" drug formulation? Not necessarily — higher bioavailability can mean faster onset but also higher peak concentrations and side-effect risk; the ideal bioavailability depends on the therapeutic goal.
Why do some drugs need to be given by injection instead of as a pill? Because they would be destroyed by stomach acid or digestive enzymes, absorbed too poorly or unpredictably from the gut, or are needed to act immediately in an emergency.
Is bioavailability the same as "how strong" a drug is? No — bioavailability measures the fraction of dose reaching circulation, not the drug's potency or efficacy once there; a low-bioavailability drug can still be very potent if dosed appropriately.
Why can't every oral drug just be reformulated to have 100% bioavailability? Because oral absorption inherently competes with digestion, first-pass metabolism, and gut transit time; some of these barriers are biological constants that formulation can only partially work around.
What's the practical reason bioequivalence testing exists? So that patients switching between brand-name and generic (or between generic manufacturers) can trust the drug will behave the same way clinically, without needing new clinical trials for every version.
Quick Revision
- Dosage form = physical delivery vehicle; route (oral, parenteral, topical, inhalation) shapes onset, duration, and bioavailability.
- Bioavailability (F) = fraction of administered dose reaching systemic circulation unchanged; IV = 100% by definition.
- First-pass metabolism = hepatic/gut-wall breakdown of orally absorbed drug before systemic circulation; major reason oral F < IV F.
- Enteric coatings delay release (protect drug from acid or stomach from drug) — this shifts timing, not necessarily total absorption.
- Controlled-release formulations lower peak concentration and extend duration, improving compliance.
- Absorption rate depends on particle size, solubility, and GI pH.
- Ferrous sulfate (higher F, more GI upset) vs. ferrous gluconate (lower F, gentler) — a classic bioavailability/tolerability trade-off.
- Bioequivalence testing ensures generic formulations perform comparably to brand-name originals despite excipient differences.
- Sublingual and transdermal routes can bypass first-pass metabolism.
- Inhalation gives fast local lung effect and can also achieve rapid systemic absorption due to high pulmonary vascularity.
Related Topics
Prerequisites: Basic Principles of Pharmacy, basic pharmacokinetics (ADME).
Related Topics: Formulation science, drug absorption physiology, generic drug regulation.
Next Topics: Advanced Pharmaceutical Technology, Biopharmaceutics and Pharmacokinetics.